December 7, 2015
Via EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Mail Stop 4720
Washington, D.C. 20549
Attn: Jim B. Rosenberg, Senior Assistant Chief Accountant
Re: AMAG Pharmaceuticals, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2014
Filed February 18, 2015
Form 10-Q for the Quarterly Period Ended September 30, 2015
Filed November 6, 2015
File No. 001-10865
Dear Mr. Rosenberg:
On behalf of AMAG Pharmaceuticals, Inc. (the Company), the Company hereby advises the staff (the Staff) of the Securities and Exchange Commission (the Commission) that the Company has received the Staffs letter dated December 2, 2015 (the Comment Letter), regarding the Commissions review of the Companys Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and the Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2015. The Company respectfully requests an extension until December 31, 2015 to respond to the Comment Letter in order to provide sufficient time for the Company to prepare the response. The Company is committed to responding to the Comment Letter promptly and intends to provide a response to the Staff no later than December 31, 2015. Should you have any questions regarding the request made herein, please do not hesitate to contact me at (617) 570-1762. Thank you very much for your courtesy and cooperation in this matter.
|
Sincerely, | |
|
| |
|
/s/ Jacqueline Mercier | |
|
Jacqueline Mercier, Esq. | |
|
Goodwin Procter LLP | |
|
| |
cc: |
Frank E. Thomas, AMAG Pharmaceuticals, Inc. |
|
|
Joseph D. Vittiglio, AMAG Pharmaceuticals, Inc. |
|
|
Ettore A. Santucci, Goodwin Procter LLP |
|